TN2013000389A1 - BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2 - Google Patents

BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2

Info

Publication number: TN2013000389A1
Authority: TN; Tunisia
Prior art keywords: dll4; ang2; binding; binding molecules; bispecific
Prior art date: 2011-04-01

Application number

TNP2013000389A

Other languages

English (en)

Inventor

Andreas Gschwind

Rene Georg Ott

Joachim Boucneau

Marie-Ange Buyse

Erik Depla

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-01

Filing date

2013-09-26

Publication date

2015-01-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44314095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000389(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-09-26 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2015-01-20 Publication of TN2013000389A1 publication Critical patent/TN2013000389A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TNP2013000389A 2011-04-01 2013-09-26 BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2 TN2013000389A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP11160920		2011-04-01
PCT/EP2012/055897 WO2012131076A1 (fr)	2011-04-01	2012-03-30	Molécules de liaison bispécifiques se liant à dll4 et ang2

Publications (1)

Publication Number	Publication Date
TN2013000389A1 true TN2013000389A1 (en)	2015-01-20

Family

ID=44314095

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000389A TN2013000389A1 (en)	2011-04-01	2013-09-26	BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2

Country Status (23)

Country	Link
US (1)	US20130078247A1 (fr)
EP (1)	EP2694545B1 (fr)
JP (1)	JP2014511682A (fr)
KR (1)	KR20140016345A (fr)
CN (2)	CN106046167A (fr)
AP (1)	AP2013007086A0 (fr)
AR (1)	AR085919A1 (fr)
AU (1)	AU2012234218A1 (fr)
BR (1)	BR112013025294A2 (fr)
CA (1)	CA2827809A1 (fr)
CL (1)	CL2013002622A1 (fr)
CO (1)	CO6801638A2 (fr)
EA (1)	EA201301109A1 (fr)
EC (1)	ECSP13012996A (fr)
MA (1)	MA35233B1 (fr)
MX (1)	MX337115B (fr)
PE (1)	PE20141157A1 (fr)
PH (1)	PH12013502031A1 (fr)
SG (1)	SG193557A1 (fr)
TN (1)	TN2013000389A1 (fr)
TW (2)	TWI551612B (fr)
UY (1)	UY33997A (fr)
WO (1)	WO2012131076A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
SI2831111T1 (sl) *	2012-03-30	2019-06-28	Boehringer Ingelheim International Gmbh	Ang2-vezavne molekule
EA201500370A1 (ru) *	2012-09-28	2015-08-31	Бёрингер Ингельхайм Интернациональ Гмбх	ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ
CA2883880A1 (fr) *	2012-09-28	2014-04-03	Boehringer Ingelheim International Gmbh	Combinaisons pharmaceutiques comprenant des liants doubles angiopoietine-2/dll4 et des agents anti-vegf
US10329556B2 (en)	2014-05-13	2019-06-25	Bioatla, Llc	Conditionally active biological proteins
CN107540747B (zh) *	2017-08-09	2020-01-24	苏州大学附属儿童医院	抗人dll4单克隆抗体6f12
CN110950967B (zh) *	2019-12-13	2022-05-13	山东民康生物科技有限公司	抗人血清白蛋白纳米抗体与il-2融合蛋白及制备方法
WO2023035226A1 (fr) *	2021-09-10	2023-03-16	深圳康哲医药发展有限公司	Anticorps anti-ang2, son procédé de préparation et son utilisation
CN116444675B (zh) *	2023-05-11	2023-12-22	亲和(武汉)生命科技有限责任公司	一种Pfu DNA聚合酶纳米抗体及其制备方法和应用
WO2025111816A1 (fr) *	2023-11-28	2025-06-05	Eluminex Biosciences Limited	Protéines de fusion multispécifiques ciblant des facteurs angiogéniques, inflammatoires et/ou fibrotiques

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2325541T3 (es)	1992-08-21	2009-09-08	Vrije Universiteit Brussel	Inmunoglobulinas desprovistas de cadenas ligeras.
EP0739981A1 (fr)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
US6329516B1 (en)	1997-04-28	2001-12-11	Fmc Corporation	Lepidopteran GABA-gated chloride channels
JP2003530839A (ja)	2000-04-12	2003-10-21	プリンシピアファーマスーティカルコーポレイション	アルブミン融合タンパク質
AU2002241922B2 (en)	2001-01-17	2007-10-25	Aptevo Research And Development Llc	Binding domain-immunoglobulin fusion proteins
JP4303105B2 (ja)	2001-06-28	2009-07-29	ドマンティスリミテッド	二重特異性リガンドとその利用
CA2484556A1 (fr)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Proteines de fusion d'albumine
EP1558647B1 (fr)	2002-11-08	2015-06-10	Ablynx N.V.	Anticorps a domaine unique diriges contre le facteur de necrose tumorale alpha et leurs utilisations
NZ540194A (en)	2002-11-08	2008-07-31	Ablynx Nv	Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2003300133B2 (en)	2002-12-31	2008-11-13	Nektar Therapeutics	Hydrolytically stable maleimide-terminated polymers
PL1639011T3 (pl)	2003-06-30	2009-05-29	Domantis Ltd	Pegilowane przeciwciała jednodomenowe (dAb)
EP2251357A1 (fr)	2003-11-07	2010-11-17	Ablynx N.V.	Anticorps VHH de domaine unique de camélidés dirigés contre le récepteur du facteur de croissance épidermique et utilisations correspondantes
US20050284249A1 (en)	2004-06-29	2005-12-29	Arnone David F	Worm type gear mover assembly
KR20070084170A (ko)	2004-10-13	2007-08-24	아블린쓰 엔.브이.	알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
HUE045710T2 (hu)	2005-05-18	2020-01-28	Ablynx Nv	Javított, alfa tumor nekrózis faktor elleni nanobodies
ES2400666T5 (es) *	2005-12-16	2016-03-10	Regeneron Pharmaceuticals, Inc.	Uso terapéutico de un antagonista de DII4 y un inhibidor de VEGF para inhibir el crecimiento tumoral
AR061246A1 (es) *	2006-06-06	2008-08-13	Genentech Inc	Anticuerpos anti- dill4 y metodos que los usan
UA94464C2 (ru) *	2006-06-06	2011-05-10	Дженентек, Инк.	Выделенное антитело к dll4 и его применение
RU2008152435A (ru) *	2006-06-06	2010-07-20	Дженентек, Инк. (Us)	Композиции и способы регулирования развития сосудов
CA2666599A1 (fr)	2006-08-18	2008-02-21	Ablynx N.V.	Sequences d'acides amines dirigees contre l'il-6r et polypeptides les contenant utilises pour le traitement de maladies et de troubles associes au signal medie par il-6
CA2663042A1 (fr) *	2006-09-08	2008-03-13	Ablynx N.V.	Proteines a demi-vie longue se liant a l'albumine serique
RU2448979C2 (ru)	2006-12-14	2012-04-27	Ридженерон Фармасьютикалз, Инк.	Антитела человека к дельта-подобному лиганду-4 человека
WO2008119353A1 (fr) *	2007-03-29	2008-10-09	Genmab A/S	Anticorps bispécifiques et procédés de production de ceux-ci
WO2009095489A2 (fr)	2008-02-01	2009-08-06	Ablynx N.V.	Séquences d'acides aminés améliorées dirigées contre il-6r et polypeptides les comprenant pour le traitement de maladies et troubles associés à une signalisation facilitée par il-6
DE112009000507T5 (de)	2008-03-05	2011-02-10	Ablynx Nv	Neue Antigen-bindende Dimerkomplexe, Verfahren zu ihrer Herstellung und ihre Verwendung
US20100260668A1 (en) *	2008-04-29	2010-10-14	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
CA2735900A1 (fr) *	2008-09-19	2010-03-25	Medimmune, Llc	Anticorps diriges contre dll4 et leurs utilisations
US8268314B2 (en) *	2008-10-08	2012-09-18	Hoffmann-La Roche Inc.	Bispecific anti-VEGF/anti-ANG-2 antibodies
JO3182B1 (ar) *	2009-07-29	2018-03-08	Regeneron Pharma	مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20110172398A1 (en) *	2009-10-02	2011-07-14	Boehringer Ingelheim International Gmbh	Bispecific binding molecules for anti-angiogenesis therapy
US20110195494A1 (en) *	2009-10-02	2011-08-11	Boehringer Ingelheim International Gmbh	Dll4-binging molecules
AR080794A1 (es) *	2010-03-26	2012-05-09	Hoffmann La Roche	Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2

2012
- 2012-03-29 US US13/433,354 patent/US20130078247A1/en not_active Abandoned
- 2012-03-30 PE PE2013002157A patent/PE20141157A1/es not_active Application Discontinuation
- 2012-03-30 CN CN201610374703.XA patent/CN106046167A/zh active Pending
- 2012-03-30 UY UY0001033997A patent/UY33997A/es unknown
- 2012-03-30 BR BR112013025294A patent/BR112013025294A2/pt not_active IP Right Cessation
- 2012-03-30 CN CN201280026737.XA patent/CN103596977B/zh not_active Expired - Fee Related
- 2012-03-30 SG SG2013070792A patent/SG193557A1/en unknown
- 2012-03-30 CA CA2827809A patent/CA2827809A1/fr not_active Abandoned
- 2012-03-30 AP AP2013007086A patent/AP2013007086A0/xx unknown
- 2012-03-30 JP JP2014501664A patent/JP2014511682A/ja not_active Ceased
- 2012-03-30 TW TW101111526A patent/TWI551612B/zh active
- 2012-03-30 MX MX2013011032A patent/MX337115B/es active IP Right Grant
- 2012-03-30 KR KR1020137028119A patent/KR20140016345A/ko not_active Withdrawn
- 2012-03-30 EP EP12711200.1A patent/EP2694545B1/fr not_active Not-in-force
- 2012-03-30 EA EA201301109A patent/EA201301109A1/ru unknown
- 2012-03-30 TW TW101111544A patent/TWI535735B/zh not_active IP Right Cessation
- 2012-03-30 WO PCT/EP2012/055897 patent/WO2012131076A1/fr not_active Ceased
- 2012-03-30 AU AU2012234218A patent/AU2012234218A1/en not_active Abandoned
- 2012-03-30 AR ARP120101129A patent/AR085919A1/es unknown
2013
- 2013-09-12 CL CL2013002622A patent/CL2013002622A1/es unknown
- 2013-09-26 TN TNP2013000389A patent/TN2013000389A1/fr unknown
- 2013-09-27 CO CO13230710A patent/CO6801638A2/es unknown
- 2013-09-27 MA MA36275A patent/MA35233B1/fr unknown
- 2013-09-30 PH PH12013502031A patent/PH12013502031A1/en unknown
- 2013-10-25 EC ECSP13012996 patent/ECSP13012996A/es unknown

Also Published As

Publication number	Publication date
AU2012234218A1 (en)	2013-09-05
CA2827809A1 (fr)	2012-10-04
MX337115B (es)	2016-02-12
CO6801638A2 (es)	2013-11-29
PE20141157A1 (es)	2014-09-24
EP2694545B1 (fr)	2016-08-24
AP2013007086A0 (en)	2013-08-31
EA201301109A1 (ru)	2014-08-29
KR20140016345A (ko)	2014-02-07
MX2013011032A (es)	2013-12-06
JP2014511682A (ja)	2014-05-19
TWI535735B (zh)	2016-06-01
CN103596977A (zh)	2014-02-19
PH12013502031A1 (en)	2013-12-16
BR112013025294A2 (pt)	2017-06-13
WO2012131076A1 (fr)	2012-10-04
MA35233B1 (fr)	2014-07-03
UY33997A (es)	2012-09-28
CL2013002622A1 (es)	2014-02-14
ECSP13012996A (es)	2013-12-31
CN103596977B (zh)	2016-07-06
TW201302789A (zh)	2013-01-16
US20130078247A1 (en)	2013-03-28
AR085919A1 (es)	2013-11-06
CN106046167A (zh)	2016-10-26
SG193557A1 (en)	2013-11-29
NZ614243A (en)	2015-04-24
EP2694545A1 (fr)	2014-02-12
TW201302797A (zh)	2013-01-16
TWI551612B (zh)	2016-10-01

Publication	Publication Date	Title
TN2013000390A1 (en)	2015-01-20	Bispecific binding molecules binding to vegf and ang2
TN2013000389A1 (en)	2015-01-20	BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2
TN2012000144A1 (en)	2013-09-19	Dll4-binding molecules
IN2014DN06904A (fr)	2015-05-15
PH12013500410B1 (en)	2022-02-11	Vegf-binding molecules
WO2014004549A3 (fr)	2014-03-13	Protéines de liaison anti-mésothéline
MY193112A (en)	2022-09-26	Anti pd-1 and anti-lag3 antibodies for cancer treatment
TN2012000145A1 (en)	2013-09-19	Bispecific binding molecules for anti-angiogenesis therapy
PH12014502527B1 (en)	2020-11-11	St2 antigen binding proteins
HK1209434A1 (en)	2016-04-01	Agents for treatment of claudin expressing cancer diseases
PH12012501838A1 (en)	2013-02-04	Aptamers to ã-ngf and their use in treating ã-ngf mediated diseases and disorders
WO2012135671A3 (fr)	2012-12-13	Anticorps monoclonaux contre inhibiteur de la voie du facteur tissulaire (tfpi)